Foghorn Therapeutics
Liguo (Vicky) Wu is an accomplished researcher and leader in the field of immunology, currently serving as VP of Research and Development at Octagon Therapeutics since July 2024, focusing on innovative therapeutics for autoimmune diseases. Previously, as Senior Director and Head of Immunology at Foghorn Therapeutics Inc., Liguo built the immunology department, overseeing strategic planning, budgeting, and talent acquisition while directing researchers to achieve aligned departmental objectives. Liguo held notable positions at Kiniksa Pharmaceuticals, Sanofi, EMD Serono, Inc., and the Broad Institute, contributing extensively to the discovery of new therapeutic targets in inflammatory conditions and mentoring scientists throughout the career. Liguo earned a Ph.D. in Immunology and Microbiology from Louisiana State University between 2001 and 2005.
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.